Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.46 USD
-0.15 (-5.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.42 -0.04 (-1.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Avenue Therapeutics, Inc. [ATXI]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Decision on IV Tramadol''s NDA Is Now Expected by March 17, 2022; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
3Q21 Recap; Awaiting Details of AdCom to Potentially Define IV Tramadol''s Regulatory Path; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Avenue Terminated SPMA With InvaGen After October 31 Deadline; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
New AdCom to Resolve Second FDRR; Just Days From Cipla''s October 31 SPMA Deadline; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Avenue Needs Funding to Further Pursue FDRR Appeal and Potential IV Tramadol Approval; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
2Q21 Recap: Formal Dispute Resolution Request Submitted; First Response Expected By August 26; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Glimmer of Hope Remains for IV Tramadol As Formal Dispute Resolution Process to Begin in 3Q21; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Second CRL Cites Delayed and Unpredictable Onset of Analgesia; Removing PT and Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
1Q21 Recap; Over a Month Past the PDUFA, Still Awaiting FDA Decision; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
4Q20 Recap; We Continue to Expect IV Tramadol Approval By April 12 But Uncertain on InvaGen Takeout; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
IV Tramadol Gets Another Shot; New PDUFA April 12; InvaGen Takeout May Still Be in Play
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
NDA Resubmission As Expected But SPMA Completion Remains Uncertain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Peer-Reviewed Publications Affirm Tramadol''s Low Likelihood For Abuse; Maintain Neutral Ahead of NDA Resubmission
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
NDA Resubmission Expected in February 2021; Potential FDA Approval as Soon as April 2021; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
3Q20 Recap: Awaiting FDA Meeting in 4Q20 to Delineate IV Tramadol''s Regulatory Path; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Could Anti-Opioid Political Pressure Be at Play in IV Tramadol CRL? Downgrade to Neutral on Unclear Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
2Q20 Recap: We Expect IV Tramadol Approval by October 10 PDUFA Date to Advance InvaGen Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
IV Tramadol''s Safety, Efficacy and Abuse Liability Assessed in Three Peer-Reviewed Articles; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E